"10.1371_journal.pone.0129954","plos one","2015-06-19T00:00:00Z","Melissa Paoloni; Christina Mazcko; Kimberly Selting; Susan Lana; Lisa Barber; Jeffrey Phillips; Katherine Skorupski; David Vail; Heather Wilson; Barbara Biller; Anne Avery; Matti Kiupel; Amy LeBlanc; Anna Bernhardt; Beatrice Brunkhorst; Robert Tighe; Chand Khanna","Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America; College of Veterinary Medicine, University of Missouri-Columbia, Columbia, Missouri, United States of America; College of Veterinary Medicine and Biological Sciences, Colorado State University, Fort Collins, Colorado, United States of America; School of Veterinary Medicine, Tufts University, North Grafton, Massachusetts, United States of America; College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, United States of America; School of Veterinary Medicine, University of California Davis, Davis, California, United States of America; School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America; College of Veterinary Medicine, Texas A&M University, College Station, Texas, United States of America; College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, United States of America; EMD-Serono Research and Development Institute, Billerica, Massachusetts, United States of America","Conceived and designed the experiments: MP CK RT. Performed the experiments: MP CM KS SL LB JP KS DV HW BJB AA MK AB BB. Analyzed the data: MP CK RT BJB AA MK AB BB. Contributed reagents/materials/analysis tools: MP CM KS SL LB JP KS DV HW BJB AA MK AB BB RT CK. Wrote the paper: MP CK KS SL LB JP KS DV HW BJB AA MK AL BB RT.","This research was supported in part by Merck KGaA. AB, BB, and RT are employees of EMD Serono, Billerica, MA, USA (a subsidiary of Merck KGaA, Darmstadt, Germany). NHS-IL12 was provided by EMD Serono, Billerica, MA. Editorial assistance was provided by Marianne Jenal-Eyholzer, PhD CMPP, TRM Oncology, The Hague, The Netherlands, funded by Merck KGaA, Darmstadt, Germany. There are no patents, products in development or marketed products to declare. This does not alter the authorsâ€™ adherence to all the PLoS ONE policies on sharing data and materials.","2015","06","Melissa Paoloni","MP",17,TRUE,3,13,8,14,TRUE,TRUE,FALSE,0,NA,FALSE
